Medline Inc.

Medline Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

Medline Inc. concluded a landmark year on December 31, 2025, marked by its transition to a public company. This summary, drawn from its recent SEC 10-K filing, offers a clear overview of Medline's operations, financial health, and strategic direction.

Business Overview: What Medline Does Medline Inc. stands as a leading healthcare company, operating through two main divisions: the Medline Brand Segment, which features its proprietary branded products, and the Supply Chain Solutions Segment, providing essential logistics and management services to healthcare providers. Medline manufactures and distributes a wide range of medical and surgical products, alongside offering comprehensive supply chain optimization services to hospitals, healthcare systems, and other care facilities.

Financial Performance: Revenue, Profit, and Year-over-Year Changes Fiscal year 2025 proved transformative for Medline, highlighted by its Initial Public Offering (IPO) on December 18, 2025. This landmark event transitioned Medline from a private to a public entity, injecting significant capital and boosting its market visibility. Medline strategically used the IPO proceeds to repay a portion of its secured debt, strengthening its financial structure.

Building on a robust growth strategy, Medline completed several key acquisitions in 2024, which are expected to contribute to its 2025 performance and future growth. These acquisitions included:

• United Medco in January 2024
• Sinclair Dental in February 2024
• Ecolab Microtek Business in August 2024

These additions expanded Medline's product portfolio, diversified its customer base, and strengthened its competitive position across various healthcare sub-markets. The capital raised through the IPO and the revenue contributions from the 2024 acquisitions are expected to positively impact the company's financial results.

Risk Factors: Key Challenges Medline faces several risks that could impact its future performance and stock price:

• Ongoing Litigation: The company is currently involved in an Intellectual Properties Case during 2025. The outcome could lead to financial penalties or operational restrictions. A "Mass Tort Litigation" case from 2019 settled in October 2023, underscoring the company's exposure to legal challenges.
• Regulatory Compliance and Fines: A significant future risk involves a "Hazardous Medical And Universal Waste Violation" related to its California facilities, which became known in February 2026 (a subsequent event to the 2025 fiscal year-end). This violation could result in substantial fines, remediation costs, and reputational damage, highlighting the stringent regulatory environment in healthcare waste management.
• Debt Burden and Interest Rate Risk: Despite repaying some debt with IPO proceeds, Medline carries a substantial amount of debt with various maturities extending to 2029 and 2030. Managing this debt, especially in a dynamic interest rate environment, remains a key financial risk, even with hedging strategies in place.
• Integration Risk: The recent 2024 acquisitions present integration challenges. Successfully realizing their anticipated benefits is crucial for Medline's sustained growth.
• Competition: Intense competition within the healthcare supply and distribution market could affect market share and pricing power.
• Supply Chain Disruptions: Reliance on global supply chains exposes the company to risks from geopolitical events, natural disasters, and other disruptions.
• Economic Conditions: General economic downturns or changes in healthcare spending could adversely affect demand for Medline's products and services.

Financial Health: Debt, Cash, and Liquidity As of December 31, 2025, Medline maintains a diversified debt structure, including both secured and unsecured obligations.

• Secured Debt: This includes various term loans (denominated in USD and EUR) and fixed-rate notes, such as 3.875% and 6.250% notes maturing in April 2029. Some variable-rate secured debt has maturities extending between 2026 and 2030.
• Unsecured Debt: This features 5.250% fixed-rate notes maturing in October 2029.

A positive development in 2025 was Medline's use of IPO proceeds to repay a portion of its secured debt, which is expected to improve the company's overall debt leverage and interest expense profile. Medline actively manages its interest rate risk through financial instruments like interest rate swaps and caps, mitigating the impact of potential rate fluctuations on its variable-rate debt. The company also maintains a revolving credit facility, providing additional liquidity and financial flexibility. The existence of a revolving credit facility and active interest rate management indicates Medline's focus on maintaining financial flexibility and mitigating risk.

Future Outlook: Guidance and Strategy Looking ahead, Medline's immediate focus will likely include addressing the Hazardous Medical And Universal Waste Violation. This will entail managing potential fines, implementing corrective actions, and ensuring ongoing regulatory compliance. The company will also continue to manage its significant debt obligations, with maturities extending through 2029 and 2030, requiring careful financial planning and potential refinancing strategies.

Medline expects the successful integration of its 2024 acquisitions and the leveraging of capital from its 2025 IPO to drive future revenue growth and profitability. Strategic priorities include continued market expansion, product innovation, and optimizing its supply chain solutions to enhance customer value and operational efficiency.

Competitive Position Medline's competitive strategy emphasizes aggressive expansion and diversification. The 2024 acquisitions of United Medco, Sinclair Dental, and Ecolab Microtek Business clearly demonstrate the company's drive to strengthen its market share, broaden its product offerings, and enhance its customer reach across different healthcare segments. Its dual-segment approach—Medline Brand and Supply Chain Solutions—allows it to address a wide range of market needs, positioning it as a comprehensive provider in the healthcare supply industry. This integrated approach, combining proprietary products with extensive distribution and logistics capabilities, provides a competitive advantage by offering end-to-end solutions to healthcare providers. Medline aims to differentiate itself through product quality, service reliability, and cost-effectiveness, leveraging its scale and operational expertise in a highly competitive market.